Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives $5.43 Average PT from Brokerages

Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) have been given an average recommendation of “Hold” by the seven analysts that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $5.43.

Several research analysts have recently issued reports on the company. Craig Hallum cut Akoya Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $7.00 to $5.00 in a research note on Friday, November 15th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price target (down previously from $4.00) on shares of Akoya Biosciences in a research note on Tuesday, November 19th. Finally, Canaccord Genuity Group cut Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th.

Hedge Funds Weigh In On Akoya Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Regal Investment Advisors LLC boosted its position in shares of Akoya Biosciences by 64.3% in the 2nd quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after purchasing an additional 7,340 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Akoya Biosciences by 16.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after purchasing an additional 9,429 shares during the period. SG Americas Securities LLC acquired a new position in shares of Akoya Biosciences in the 4th quarter valued at $28,000. State Street Corp boosted its position in shares of Akoya Biosciences by 4.2% in the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock valued at $1,233,000 after purchasing an additional 18,361 shares during the period. Finally, Barclays PLC boosted its position in shares of Akoya Biosciences by 320.9% in the 3rd quarter. Barclays PLC now owns 39,472 shares of the company’s stock valued at $107,000 after purchasing an additional 30,095 shares during the period. Institutional investors and hedge funds own 79.42% of the company’s stock.

Akoya Biosciences Trading Down 0.3 %

NASDAQ:AKYA opened at $2.99 on Friday. Akoya Biosciences has a 1 year low of $1.88 and a 1 year high of $6.31. The stock has a market cap of $148.21 million, a price-to-earnings ratio of -2.53 and a beta of 1.18. The business has a fifty day moving average of $2.53 and a 200-day moving average of $2.61. The company has a debt-to-equity ratio of 5.62, a quick ratio of 1.85 and a current ratio of 2.75.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.